The annual incidence of myasthenia gravis (MG) ranges from 3 to 30 per 1,000,000 people. Since the mid-1980s, an increasing incidence has been reported, mainly due to late-onset MG. Whether the increase was due to population aging, improved diagnosis and case collection, or a true excess of incidence cases is still under debate. We used a complete enumeration approach by reviewing all possible sources of case collection in the province of Ferrara, Italy, to estimate the MG incidence and its temporal trend over the study period (1985–2007). The mean annual age-adjusted incidence of MG was 18 per 1,000,000, without any significant temporal trend. The incidence rates in the period 1985–1990 were 14 both for early and late-onset MG. Thereafter, a significant increase in incidence of late-onset MG (p < 0.05), and a decrease in early onset MG were detected (p < 0.01). These findings were related to nonthymoma MG. The median age at onset of the disease steadily increased over time. A changing pattern of MG incidence with an increase in frequency of late-onset and a decrease of early onset MG was found in the last years, giving a significant shift to older age at onset of the disease. Unknown environmental factors may have driven this change in MG epidemiology.
Myasthenia gravis Epidemiology Incidence
This is a preview of subscription content, log in to check access.
This work was supported by grants from the Italian Ministry of University and from Fondazione Cassa di Risparmio di Ferrara.
Conflict of interest statement
The authors declare that they have no conflicts of interest.
McGrogan A, Sneddon S, de Vries CS (2010) The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology 34:171–183CrossRefPubMedGoogle Scholar
Phillips LH 2nd, Tomer JC, Anderson MS, Cox GM (1992) The epidemiology of myasthenia gravis in central and western Virginia. Neurology 42:1888–1893PubMedGoogle Scholar
Aragones JM, Bolibar I, Bonfill X, Bufill E, Mummany A, Alonso F, Illa I (2003) Myasthenia gravis. A higher-than-expected incidence in the elderly. Neurology 60:1024–1026CrossRefPubMedGoogle Scholar
Somnier FE (2005) Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis. Neurology 65:928–930CrossRefPubMedGoogle Scholar
Matsui N, Nakane S, Nakagawa Y, Kondo K, Mitsui T, Matsumoto T, Arisaswa K, Kaji R (2009) Increasing incidence of elderly onset patients with myasthenia gravis in a local area of Japan. J Neurol Neurosurg Psychiatry 80:1168–1171CrossRefPubMedGoogle Scholar
Vincent A, Clover L, Buckley C, Grimley Evans J, Rothwell PM, the UK myasthenia gravis survey (2003) Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry 74:1105–1108CrossRefPubMedGoogle Scholar
Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Myasthenia Gravis (2000) Recommendation for clinical research standards. Neurology 55:16–23Google Scholar
Somnier FE, Keiding N, Paulson OB (1991) Epidemiology of Myasthenia Gravis in Denmark. A longitudinal and comprehensive population survey. Arch Neurol 48:733–739PubMedGoogle Scholar
Robertson NP, Deans J, Compston DAS (1998) Myasthenia gravis: a population based epidemiological study in Cambridgeshire England. J Neurol Neurosurg Psychiatry 65:492–496CrossRefPubMedGoogle Scholar
Poulas K, Tsibri E, Kokla A, Papanastasiou D, Tsouloufis T, Marinou M, Tsantili P, Papapetropoulos T, Tzartos SJ (2001) Epidemiology of myasthenia gravis in Greece. J Neurol Neurosurg Psychiatry 71:352–356CrossRefPubMedGoogle Scholar
Heldal AT, Owe JF, Gilhus NE, Romi F (2009) Seropositive myasthenia gravis: a nationwide epidemiologic study. Neurology 73:150–151CrossRefPubMedGoogle Scholar
Emilia-Romagna Study Group on Clinical, Epidemiological Problems in Neurology (1998) Incidence of myasthenia gravis in the Emilia-Romagna region: a prospective multicenter study. Neurology 51:255–258Google Scholar
Casetta I, Fallica E, Govoni V, Azzini C, Tola M, Granieri E (2004) Incidence of myasthenia gravis in the province of Ferrara. A community-based study. Neuroepidemiology 23:281–284CrossRefGoogle Scholar
Compston DA, Vincent A, Newsom-Davis J, Batchelor JR (1980) Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 103:579–601CrossRefPubMedGoogle Scholar